CHGCF - Gilead's Remdesivir To Miss End Stage COVID-19 Market But It Doesn't Matter
The value of proper clinical trials is that they give results that give confidence in the efficacy (or otherwise) of drugs. The UK has a complex major trial (RECOVERY) for testing drugs for treating COVID-19. Recent results from this trial were pivotal in the FDA deciding that hydroxychloroquine is ineffective and withdrawing its EUA (Emergency Use Authorization) for use of this drug in treating COVID-19. Now, RECOVERY has reported results from use of an old low-cost steroidal drug dexamethasone. It shows for the first time a reduction of deaths in end stage COVID-19 patients. Here,